



Pancreatic cancer trials open to recruitment – April/May 2026

This list includes trials targeted at pancreatic cancer alone and trials for many solid tumours which include pancreatic cancer. If you are a patient with pancreatic cancer and wish to discuss whether a clinical trial is right for you, please discuss with your treating Medical Oncologist.

NOTE: Trials listed are available for patients with pancreatic cancer to be referred for consideration. Several trials may have issues with slot availability or waitlists.

Descriptive stages of pancreatic cancer

Medical Term	What it means
Resectable	This is an early stage of pancreatic cancer where the cancer can still be removed by surgery
Unresectable or locally advanced	The pancreatic cancer has not spread around the body but unfortunately the cancer cannot be removed by surgery due to the tumour size, location, or involvement of surrounding structures
Metastatic	The pancreatic cancer has spread to other parts of the body



PANCREATIC CANCER TRIALS IN VICTORIA (Trials with specific cohorts for pancreatic cancer)					
Trial Title	Targets (Genomic)	Target population <i>(Trial suitable for patients with this stage of pancreatic cancer)</i>	Treatment + Further Information <i>(What the study involves)</i>	Site <i>(Where the study is being offered)</i>	Contact Details <i>(Email the contact person listed with any enquiries)</i>
NeoFOL-R Efficacy of Neoadjuvant FOLFIRINOX in Resectable pancreatic cancer: An international multicentre Randomized, controlled trial (NeoFOL-R) - Australian protocol	N/A	RESECTABLE Exclusion: Borderline resectable Locally advanced Previous treatment for pancreatic cancer	mFOLFIRINOX chemotherapy Arm A: Surgery then 12 cycles of chemotherapy Arm B: 6 cycles of chemotherapy before surgery followed by 6 of cycles after surgery Further information: NeoFOL-R - Victorian Cancer Trials Link	Epworth Health	EHJreissatiCentre@epworth.org.au
				Monash Health	gi.oncresearch@monashhealth.org
				Alfred Health	act-m@alfred.org.au
River (C3651021) A Study to Learn About the Medicine Pongegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue	GDF-15	METASTATIC/LOCALLY ADVANCED <i>(First line)</i> Inclusion: Metastatic pancreatic ductal adenocarcinoma Can have received first cycle of chemotherapy but prior to second cycle Cachexia defined by Fearon criteria of weight loss	Pongegromab Pongegromab is a monoclonal antibody aiming to treat cancer cachexia for targeting GDF-15 Patients are treated with first line chemotherapy (gemcitabine + nab-paclitaxel or mFOLFIRINOX) and randomized to receive pongegromab or placebo Further information: https://clinicaltrials.gov/study/NCT06989437	Western Health	CancerClinicalTrials@wh.org.au



PANCREATIC CANCER TRIALS IN VICTORIA (Trials with specific cohorts for pancreatic cancer)					
Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
CA240-0030 / MountainTAP-30 A Randomized, Phase 2/3 Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion	MTAP deletion	METASTATIC/LOCALLY ADVANCED (First line) Inclusion: Untreated advanced pancreatic cancer Homozygous MTAP deletion	BMS-986504 Patients will receive gemcitabine and nab-paclitaxel combined with BMS-986504 (a novel PRMT5 inhibitor) or placebo. Further information: https://trials.cancervic.org.au/details/vct1_nct07076121	Cabrini	clinicaltrials@cabrini.com.au
				Northern Hospital	cancerclinicaltrials@nh.org.au
FMT Fecal Microbiota Transplantation to improve pain, symptom management and treatment efficacy in patients with pancreatic cancer	N/A	METASTATIC/LOCALLY ADVANCED (First line) Inclusion: Pancreatic cancer Exclusion: Antibiotic use within 8 weeks of randomisation (1 dose with ERCP allowed)	Fecal Microbiota Transplantation Further information: https://www.pancreaticcentre.org.au/treatment/clinical-trials-and-research/fmt	Epworth	EH-PancreaticCentre@epworth.org.au
LuMIERE A Phase 1/2, Multicentre, Open-label, Non-randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of 177Lu-FAP-2286 in Patients With an Advanced	FAP	METASTATIC/LOCALLY ADVANCED (First line) Inclusion: Pancreatic ductal adenocarcinoma + other cancers	[177Lu]Lu-FAP-2286 [177Lu]Lu-FAP-2286 is a radiopharmaceutical that targets fibroblast activation protein (FAP). This treatment works by binding to the FAP to allow the targeted delivery of radiation	Alfred Health	act-m@alfred.org.au



PANCREATIC CANCER TRIALS IN VICTORIA (Trials with specific cohorts for pancreatic cancer)					
Trial Title	Targets (Genomic)	Target population <i>(Trial suitable for patients with this stage of pancreatic cancer)</i>	Treatment + Further Information <i>(What the study involves)</i>	Site <i>(Where the study is being offered)</i>	Contact Details <i>(Email the contact person listed with any enquiries)</i>
Solid Tumour		Combination cohort: Chemotherapy naive for advanced disease Exclusion: Active CNS disease	directly to FAP-expressing cancer cells. Further information: https://trials.cancervic.org.au/details/vct1_nct04939610	Peter MacCallum Cancer Centre	PCCTU.MoncC@petermac.org
AMG193 20230223 A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 in Combination with Other Therapies in Subjects with Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers with Homozygous MTAP-deletion AMG20230223	MTAP deletion	METASTATIC/LOCALLY ADVANCED <i>(Second line)</i> Inclusion: Pancreatic cancer Homozygous MTAP-deletion Exclusion: Prior MAT2A inhibitor or PRMT5 inhibitor	AMG 193 AMG 193 is a PMRT5 inhibitor which is administered orally. Further information: https://trials.cancervic.org.au/details/vct1_nct06360354	Peter MacCallum Cancer Centre	PCCTU.MoncC@petermac.org
				Austin Health	samantha.chakar@austin.org.au
PemOla A phase II study combining pembrolizumab with olaparib in metastatic pancreatic adenocarcinoma patients with mismatch repair deficiency or tumour mutation burden > 4 mutations/ Mb	dMMR/MS I-high or TMB > 4 mutations / Mb	METASTATIC/LOCALLY ADVANCED <i>(Second line)</i> Inclusion: Pancreatic cancer	Pembrolizumab and Olaparib Pembrolizumab in anti-PD1 antibody Olaparib is a PARP inhibitor Further information: https://trials.cancervic.org.au/details/vct1_nct05093231	Monash Health	Gi.oncresearch@monashhealth.org
				Epworth	EH-PancreaticCentre@epworth.org.au
PAUF-I * NO SLOTS CURRENTLY AVAILABLE* A First in Human, Phase 1/2a, Multicentre, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of	PAUF	METASTATIC/LOCALLY ADVANCED <i>(Second line +)</i> Inclusion: Received at least 1 line of	PBP1510 PBP1510 is an IgG1 monoclonal antibody (mAb) that targets and neutralises PAUF.	Monash Health	referrals.earlyphase@monashhealth.org * NO SLOTS CURRENTLY AVAILABLE*



PANCREATIC CANCER TRIALS IN VICTORIA (Trials with specific cohorts for pancreatic cancer)					
Trial Title	Targets (Genomic)	Target population <i>(Trial suitable for patients with this stage of pancreatic cancer)</i>	Treatment + Further Information <i>(What the study involves)</i>	Site <i>(Where the study is being offered)</i>	Contact Details <i>(Email the contact person listed with any enquiries)</i>
PBP1510 in Patients with Advanced/Metastatic Pancreatic Cancer		chemotherapy and progressed	Further information: https://trials.cancervic.org.au/details/vct1_nct05141149		
<u>INCB161734</u> A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation	KRAS G12D	ADVANCED OR METASTATIC SOLID CANCERS <i>(Second line +)</i> Inclusion: Second line and beyond	<u>INCB161734</u> INCB161734 in a KRAS G12D inhibitor Further information: https://trials.cancervic.org.au/details/vct1_nct06179160	Alfred Health	act-m@alfred.org.au
<u>AP601</u> A Study of AP601 in Patients With Locally Unresectable Advanced or Metastatic Solid Tumors	CD73 + CD137	ADVANCED OR METASTATIC SOLID CANCERS <i>(Second line +)</i> Inclusion: Pancreatic ductal adenocarcinoma	<u>AP601</u> AP601 is a bispecific antibody that targets and inhibits CD73 on tumour cells and activates CD137 on T cells. AP601 is delivered as an infusion. Further information: https://www.pancreaticcentre.org.au/treatment/clinical-trials-and-research/ap601	Epworth	EH-PancreaticCentre@epworth.org.au
<u>AMG 410</u> A Phase 1/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors	KRAS	ADVANCED OR METASTATIC SOLID CANCERS <i>(Exhausted standard of care)</i> Inclusion: KRAS mutation or amplification Exhausted conventional treatment options Pancreatic cohort specified in part 2.	<u>AMG 410</u> AMG 410 is an oral pan-KRAS inhibitor and will be administered alone or in combination with pembrolizumab and panitumumab Further information: https://trials.cancervic.org.au/details/vct1_nct07094113	Peter MacCallum Cancer Centre	PCCTU.EDD@petermac.org



PANCREATIC CANCER TRIALS IN VICTORIA (Trials with specific cohorts for pancreatic cancer)					
Trial Title	Targets (Genomic)	Target population <i>(Trial suitable for patients with this stage of pancreatic cancer)</i>	Treatment + Further Information <i>(What the study involves)</i>	Site <i>(Where the study is being offered)</i>	Contact Details <i>(Email the contact person listed with any enquiries)</i>
<u>ELK1004-101</u> A Phase 1/2, Open-label, Multicenter, Dose-escalation, and Dose-Optimization Study to Evaluate the Safety, Tolerability, and Activity of EIK1004 (IMP1707) as Monotherapy in Participants With Advanced Solid Tumors	HRR deficiency	METASTATIC/LOCALLY ADVANCED <i>(Second line +)</i> Inclusion: Suspected deleterious mutation of select HRR genes Exclusion: Prior PARP1 inhibitor	<u>EIK1004</u> EIK1004 is an oral PARP1 inhibitor and will be administered as monotherapy Further information: https://trials.cancervic.org.au/details/vct1_nct06907043	Peninsula and South Eastern Haematology and Oncology Group	ag@paso.com.au
<u>EIK1005-002</u> A Multicenter, Multi-Part, Phase 1/2 Study of EIK1005 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors, Including Checkpoint Inhibitor Naive Participants With Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors	WRN (Werner helicase) + dMMR/MSI-H	METASTATIC/LOCALLY ADVANCED <i>(Second line +)</i> Inclusion: Part 1a – all patients Part 1b and 2: Confirmed dMMR or MSI-H tumours	<u>EIK1005</u> ELK1005 is a potent and selective inhibitor of WRN and is administered orally. Participants with receive ELK1005 as monotherapy or in combination with pembrolizumab Further information: https://trials.cancervic.org.au/details/vct1_nct07262619#	Grampians Health (Ballarat)	clinicaltrials@gh.org.au



SOLID CANCER TRIALS ACCEPTING PANCREATIC CANCER IN VICTORIA					
Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
<p>BGB 58067</p> <p>A Phase 1a/b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-58067, an MTA-Cooperative PRMT5 Inhibitor in Patients With Advanced Solid Tumors</p>	MTAP loss	<p>ADVANCED OR METASTATIC SOLID CANCERS</p> <p>Inclusion: MTAP loss (pre-screening available)</p> <p>Exclusion: Prior treatment with PRMT5 or MAT2A inhibitor</p>	<p><u>BGB-58067</u></p> <p>BGB-58067 is an MTA-Cooperative PRMT5 inhibitor.</p> <p>Further information: NCT06589596 - Victorian Cancer Trials Link</p>	<p>Monash Health</p> <p>(Note: Austin Health is only recruiting GBM)</p>	referrals.earlyphase@monashhealth.org
<p>CS5001</p> <p>A Phase I, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activities of CS5001, an Anti-ROR1 Antibody-Drug Conjugate, Used as A Single Agent and in Combination with Systemic Therapies in Patients with Advanced Solid Tumors and Lymphomas.</p>	ROR1	<p>ADVANCED OR METASTATIC SOLID CANCERS</p> <p>Inclusion: Progression on at least 1 prior line of systemic therapy ECOG 0-1</p>	<p><u>CS5001</u></p> <p>CS5001 in an antibody drug conjugate targeting ROR1</p> <p>Further information: https://www.pancreaticcentre.org.au/treatment/clinical-trials-and-research/cs5001</p>	Epworth	<p>connie.barlas@epworth.org.au or</p> <p>EH-PancreaticCentre@epworth.org.au</p>
<p>AT-0174-001</p> <p>* RECRUITMENT ON HOLD*</p> <p>A Phase I Study to Evaluate the Safety, Tolerability, Pharmacology, and Preliminary Efficacy of AT-0174 in Subjects with Advanced Solid Malignancies</p>	IDO1/TDO2	<p>ADVANCED OR METASTATIC SOLID CANCERS</p> <p>Inclusion: Progressed on available prior lines of therapy</p> <p>***ON HOLD***</p>	<p><u>AT-0174</u></p> <p>AT-0174 is a novel dual inhibitor of IDO1/TDO2</p> <p>Further information: https://trials.cancervic.org.au/details/vct1_actrn12623000956606</p>	<p>Grampians Health (Ballarat)</p> <p>St Vincent's Hospital Melbourne</p>	<p>clinicaltrials@gh.org.au</p> <p>OncologyTrialCoordinators@svha.org.au</p> <p>* RECRUITMENT ON HOLD*</p>



SOLID CANCER TRIALS ACCEPTING PANCREATIC CANCER IN VICTORIA					
Trial Title	Targets (Genomic)	Target population <i>(Trial suitable for patients with this stage of pancreatic cancer)</i>	Treatment + Further Information <i>(What the study involves)</i>	Site <i>(Where the study is being offered)</i>	Contact Details <i>(Email the contact person listed with any enquiries)</i>
<p><u>AKTive-001</u></p> <p>* RECRUITMENT ON HOLD*</p> <p>A Phase 1/1b Multiple Cohort Trial of ALTA2618 in Patients with Advanced Solid Tumors with AKT1 E17K Mutation</p>	<p>AKT E17K mutation</p>	<p>ADVANCED OR METASTATIC SOLID CANCERS</p> <p>Inclusion: Exhausted standard of care therapies</p> <p>Exclusion: Prior mTOR or PI3K inhibitors Presence of KRAS, NRAS, HRAS or BRAF genomic alterations</p>	<p><u>ALTA2618</u></p> <p>ALTA2618 is an oral AKT E17K inhibitor</p> <p>Further information: https://trials.cancervic.org.au/details/vct1_nct06533059</p>	<p>Cabrini</p>	<p>clinicaltrials@cabrini.com.au</p> <p>* RECRUITMENT ON HOLD*</p>
<p><u>AMT-676-01</u></p> <p>* NO SLOTS CURRENTLY AVAILABLE*</p> <p>First-in-Human, Phase 1 Study of AMT-676, an Anti-CDH17 Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors</p>	<p>CDH17</p>	<p>ADVANCED OR METASTATIC SOLID CANCERS</p> <p>Inclusion: Second or later line therapy</p>	<p><u>AMT-676</u></p> <p>AMT-676 is an anti-CDH17 antibody drug conjugate.</p> <p>Further information: https://trials.cancervic.org.au/details/vct1_nct06400485</p>	<p>Cabrini</p>	<p>clinicaltrials@cabrini.com.au</p> <p>* NO SLOTS CURRENTLY AVAILABLE*</p>
<p><u>D3S-001-100</u></p> <p>A Phase 1, Open Label, Dose Escalation and Dose Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3S 001 Monotherapy in Subjects with Advanced Solid Tumors with a KRAS p.G12C Mutation</p>	<p>KRAS G12C</p>	<p>ADVANCED OR METASTATIC SOLID CANCERS</p> <p>Inclusion: KRAS G12C mutation</p> <p>*Note pancreatic specific cohort has closed. Pantumour cohort remains open with limited slots</p>	<p><u>D3S 001</u></p> <p>D3S 001 is a KRAS G12C inhibitor</p> <p>Further information: https://trials.cancervic.org.au/details/feed-cta-trial449</p>	<p>Peter MacCallum Cancer Centre</p>	<p>PCCTU.EDD@petermac.org</p>



SOLID CANCER TRIALS ACCEPTING PANCREATIC CANCER IN VICTORIA					
Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
<p><u>GDC-7035</u></p> <p>A Phase I/II Dose-Escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors With a KRAS G12D Mutation</p>	<p>KRAS G12D</p>	<p>ADVANCED OR METASTATIC SOLID CANCERS</p> <p>Inclusion: KRAS G12D mutation</p>	<p><u>GDC-7035</u></p> <p>GDC-7035 is a KRAS G12D inhibitor. Treatment will be monotherapy or in combination with other anti-cancer treatments.</p> <p>Further information: https://trials.cancervic.org.au/details/vct/nct06619587</p>	<p>Peter MacCallum Cancer Centre</p>	<p>PCCTU.EDD@petermac.org</p>
<p><u>BG-C477</u></p> <p>* RECRUITMENT ON HOLD*</p> <p>A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-C477 in Patients With Selected Advanced Solid Tumors</p>	<p>CEACAM5</p>	<p>ADVANCED OR METASTATIC SOLID CANCERS</p> <p>Inclusion: CEA >5</p>	<p><u>BG-C477</u></p> <p>BG-C477 is an antibody-drug conjugate targeting CEACAM5. BG-C477 will be delivered as monotherapy or in combination with capecitabine and bevacizumab.</p> <p>Further information: https://trials.cancervic.org.au/details/vct/nct06596473</p>	<p>Alfred Health</p>	<p>act-m@alfred.org.au</p> <p>* RECRUITMENT ON HOLD*</p>
<p><u>AMT-562-01</u></p> <p>First-in-Human, Phase 1 Study of AMT-562, an Anti HER3 Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors</p>	<p>HER3</p>	<p>ADVANCED OR METASTATIC SOLID CANCERS</p> <p>Inclusion: Second line and beyond</p>	<p><u>AMT-562</u></p> <p>AMT-562 is a novel HER3 targeting antibody drug conjugate.</p> <p>Further information: https://trials.cancervic.org.au/details/vct/nct06199908</p>	<p>Cabrini</p>	<p>clinicaltrials@cabrini.com.au</p>



SOLID CANCER TRIALS ACCEPTING PANCREATIC CANCER IN VICTORIA

Trial Title	Targets (Genomic)	Target population <i>(Trial suitable for patients with this stage of pancreatic cancer)</i>	Treatment + Further Information <i>(What the study involves)</i>	Site <i>(Where the study is being offered)</i>	Contact Details <i>(Email the contact person listed with any enquiries)</i>
<p><u>IKS014-01 (IKSUDA)</u></p> <p>* NO SLOTS CURRENTLY AVAILABLE*</p> <p>A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS014, a HER2-Targeting Antibody Drug Conjugate (ADC), in Participants With Advanced HER2+ Solid Tumors</p>	HER2	<p>ADVANCED OR METASTATIC SOLID CANCERS</p> <p>Inclusion: HER2 IHC 1-3+ HER2 ISH negative and positive</p>	<p>IKS014</p> <p>IKS014 is a HER2 targeting antibody drug conjugate.</p> <p>Further information: https://trials.cancervic.org.au/details/vctlnct05872295</p>	Peninsula and Southeast Oncology	<p>ag@paso.com.au</p> <p>* NO SLOTS CURRENTLY AVAILABLE*</p>
<p><u>Stingray SR-8541A-001</u></p> <p>Phase 1, Dose Escalation, Safety, Tolerability, and Pharmacokinetic Study of SR-8541A (ENPP1 Inhibitor) Administered Orally as Monotherapy in Subjects With Advanced/Metastatic Solid Tumors</p>	ENPP1	<p>ADVANCED OR METASTATIC SOLID CANCERS</p> <p>Inclusion: Exhausted conventional treatment</p>	<p>SR-8541A</p> <p>SR-8541A is an ENPP1 inhibitor.</p> <p>Further information: https://trials.cancervic.org.au/details/vctlnct06063681</p>	Peninsula and Southeast Oncology	ag@paso.com.au
<p><u>BAY3498264</u></p> <p>Phase 1 Study of a SOS1 Inhibitor, BAY 3498264, in Combination in Participants With Advanced KRASG12C-mutated Solid Tumors</p>	SOS1 KRAS	<p>ADVANCED OR METASTATIC SOLID CANCERS</p> <p>Inclusion: KRAS G12C mutation</p>	<p>BAY3498264</p> <p>BAY3498264 is a SOS1 inhibitor. Treatment will be in combination with sotorasib.</p> <p>Further information: https://trials.cancervic.org.au/details/vctlnct06659341</p>	Peninsula and Southeast Oncology	ag@paso.com.au



SOLID CANCER TRIALS ACCEPTING PANCREATIC CANCER IN VICTORIA					
Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
<p>AK138D1</p> <p>A First-in-human, Phase I Study of Evaluating Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AK138D1 in the Treatment of Advanced Solid Tumors</p>	HER3	<p>ADVANCED OR METASTATIC SOLID CANCERS</p> <p>Inclusion: Exhausted conventional treatment</p>	<p>Patritumab Deruxtecan</p> <p>Patritumab Deruxtecan an anti-HER3 Antibody drug conjugate</p> <p>Further information: https://trials.cancervic.org.au/details/vct1_nct06730386</p>	Peninsula and Southeast Oncology	ag@paso.com.au
<p>DT-7012-CLI-001</p> <p>Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors (DOMISOL)</p>	CCR8	<p>ADVANCED OR METASTATIC SOLID CANCERS</p> <p>Inclusion: Second or later line</p>	<p>DT-7012</p> <p>DT-7012 is an anti-CCR8 antibody.</p> <p>Further information: https://clinicaltrials.gov/study/NCT06819735</p>	Peninsula and Southeast Oncology	ag@paso.com.au
<p>SNV4818</p> <p>A Phase 1, Open-Label Dose Escalation and Expansion Study of SNV4818 as Monotherapy or in Combination With Other Anticancer Agents in Participants With Advanced Solid Tumors</p>	PIK3CA	<p>ADVANCED OR METASTATIC SOLID CANCERS</p> <p>Inclusion: Activating PIK3CA mutation Exhausted conventional treatment</p> <p><i>Note: Pantumour for dose escalation cohorts</i></p>	<p>SNV4818</p> <p>SNV4818 is an oral PI3Kα inhibitor. SNV4818 will be delivered with or without fulvestrant</p> <p>Further information: NCT06736704 - Victorian Cancer</p>	Monash Health	referrals.earlyphase@monashhealth.org
<p>BM230</p> <p>* RECRUITMENT ON HOLD*</p> <p>A Phase I, Multicenter, Non-randomized, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BM230 in Patients With Advanced</p>	HER2	<p>ADVANCED OR METASTATIC SOLID CANCERS</p> <p>Inclusion: HER2 1+ expression</p> <p>**On hold**</p>	<p>BM230</p> <p>BM230 is delivered subcutaneously each week for 3 weeks followed by fortnightly administration</p> <p>Further information:</p>	Monash Health	* RECRUITMENT ON HOLD*



SOLID CANCER TRIALS ACCEPTING PANCREATIC CANCER IN VICTORIA					
Trial Title	Targets (Genomic)	Target population <i>(Trial suitable for patients with this stage of pancreatic cancer)</i>	Treatment + Further Information <i>(What the study involves)</i>	Site <i>(Where the study is being offered)</i>	Contact Details <i>(Email the contact person listed with any enquiries)</i>
Solid Tumors			BM230 - Victorian Cancer Trials		
<u>BNT317</u> A Phase I, First-in-human, Open-label, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BNT317 in Patients with Advanced Solid Tumors	CD39	ADVANCED OR METASTATIC SOLID CANCERS Inclusion: Exhausted conventional treatment	<u>BT317</u> BT317 is administered intravenously Further information: NCT06750185 - Victorian Cancer Trials Link	Monash Health	referrals.earlyphase@monashhealth.org
<u>OZ-001-101</u> A Phase 1, Open-label, First-in Human Study to Examine the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of OZ-001 when Administered Orally in Adults with Solid Tumours with a Focus on Triple Negative Breast Cancer	STAT3	ADVANCED OR METASTATIC SOLID CANCERS Inclusion: Exhausted conventional treatment Confirmed accepting PDAC for phase 1a	<u>OZ-001</u> OZ-001 is a small molecule dual inhibitor of the STAT3 and T-type calcium channels Further information: https://trials.cancervic.org.au/details/vct1_actrn12625000163404	Peninsula and South Eastern Haematology and Oncology Group	ag@paso.com.au
<u>INI-4001-101</u> * NO SLOTS CURRENTLY AVAILABLE* An Open-label, Multiple-Ascending Dose, Two-Part Dose Ranging and Cohort Expansion Study of INI-4001 in Patients with Advanced Solid Tumours	TLR7/8	ADVANCED OR METASTATIC SOLID CANCERS Inclusion: Exhausted conventional treatment Pre-screening component (review of medical history)	<u>INI-4001</u> INI-4001 is TLR7/8 agonist. Further information: https://trials.cancervic.org.au/details/vct1_nct06302426	Cabrini	clinicaltrials@cabrini.com.au * NO SLOTS CURRENTLY AVAILABLE*



SOLID CANCER TRIALS ACCEPTING PANCREATIC CANCER IN VICTORIA					
Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
LM350-01-10 A Phase I/II, First-in-Human (FIH), Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM-350 in Patients with Advanced Solid Tumors	CDH17	ADVANCED OR METASTATIC SOLID CANCERS Inclusion: Exhausted conventional treatment	LM350 LM350 is a CDH17 targeted antibody drug conjugate Further information: https://clinicaltrials.gov/study/NCT07112222?aggFilters=status:not	Peninsula and South Eastern Haematology and Oncology Group	ag@paso.com.au
RO7673396 A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Clinical Activity of RO7673396 as a Single Agent and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors Harboring RAS Mutation(s)	RAS	ADVANCED OR METASTATIC SOLID CANCERS Inclusion: Exhausted conventional treatment Confirmed presence of RAS mutation	RO7673396 RO7673396 is an oral RAS inhibitor Further information: https://trials.cancervic.org.au/details/vct1_nct06884618	Peter MacCallum Cancer Centre	PCCTU.EDD@petermac.org
TLN-372 (Treeline T1) An Open-Label, Multicenter, Phase 1 Trial to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of TLN-372 as a Single Agent and in Combination With Other Anti-Tumor Agents, in Patients With Advanced KRAS Mutant Solid Tumors	KRAS	ADVANCED OR METASTATIC SOLID CANCERS Inclusion: Second line onwards	TLN-372 TLN-372 is a pan-KRAS inhibitor that will be administered as monotherapy or in combinations with cetuximab and pembrolizumab. Further information: https://trials.cancervic.org.au/details/vct1_nct07204340	Peter MacCallum Cancer Centre	PCCTU.EDD@petermac.org



SOLID CANCER TRIALS ACCEPTING PANCREATIC CANCER IN VICTORIA					
Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
<u>IDOV-Immune for Advanced Solid Tumors</u> A First-in-human, Phase I, Multi-center, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Evidence of Antitumor Activity of IDOV-Immune in Adult Participants With Advanced Solid Tumors	N/A	ADVANCED OR METASTATIC SOLID CANCERS Inclusion: Exhausted conventional treatment	<u>IDOV-Immune</u> IDOV-immune is an oncolytic virus therapy administered intravenously. Patients will receive one dose of therapy. Further information: https://trials.cancervic.org.au/details/vct1_nct06910657?utm_source=ccv-website&utm_medium=website&utm_campaign=api	Alfred Health	act-m@alfred.org.au
<u>KIVU-107-01</u> * NO SLOTS CURRENTLY AVAILABLE* This is a 2-part, first-in-human, open-label study to determine the safety and tolerability of KIVU-107, a PTK7-directed antibody-drug conjugate, in participants with locally advanced or metastatic solid tumors.	PTK7	ADVANCED OR METASTATIC SOLID CANCERS Inclusion: Exhausted conventional treatment	<u>KIVU-107</u> KIVU-107 is a PTK7-directed antibody-drug conjugate. Further information: https://clinicaltrials.gov/study/NC07229313	Barwon Health	cstu.manager@barwonhealth.org.au * NO SLOTS CURRENTLY AVAILABLE*



SUPPORTIVE CARE TRIALS FOR PATIENTS WITH PANCREATIC CANCER					
Trial Title	Targets (Genomic)	Target population <i>(Trial suitable for patients with this stage of pancreatic cancer)</i>	Treatment + Further Information <i>(What the study involves)</i>	Site <i>(Where the study is being offered)</i>	Contact Details <i>(Email the contact person listed with any enquiries)</i>
<u>DINE-PC</u> Dietetics Intervention and Nutritional Evaluation in Pancreatic Cancer Care (DINE-PC)	N/A	ALL STAGES OF PANCREATIC CANCER	<u>Dietetics counselling</u> Further information: https://www.pancreaticcentre.org.au/treatment/clinical-trials-and-research/dine-pc	Epworth Victoria	EH- PancreaticCentre@epworth.org.au
<u>SuperQol:</u> Assessing the impact of an intensive dietitian-led telehealth intervention focusing on nutritional adequacy and symptom control, on quality of life in patients with pancreatic cancer: a randomised controlled trial	N/A	ALL STAGES OF PANCREATIC CANCER	<u>Dietician counselling/intervention</u> Patients will be randomised to receive usual care or intensive dietetics intervention Further intervention: https://trials.cancervic.org.au/details/vctl_actrn12624000084583	Latrobe Regional Hospital Victoria	clinicaltrials@lrh.com.au



<p>PANConnect Assessing the effectiveness of a specialist cancer nurse-led telehealth model of care on pain and symptom management among Australians affected by pancreatic cancer: The PANConnect randomised controlled trial</p>	<p>N/A</p>	<p>ALL STAGES OF PANCREATIC CANCER</p>	<p><u>PANConnect intervention</u></p> <p>Participants allocated to the <u>PANConnect intervention</u> will continue to receive oncology care from their treating team.</p> <p>PANConnect comprises: Weekly patient symptom-reporting plus symptom assessment and subsequent care coordination by a specialist cancer nurse</p> <p>Further information: https://trials.cancervic.org.au/details/vct1_actrn12624001034527</p>	<p>Austin Health Bendigo Health Border Medical Oncology Monash Health Peninsula Health Peter MacCallum Cancer Centre St Vincent's Hospital Melbourne Warringal Private Hospital</p>	<p>PANConnect-Study@petermac.org</p>
---	------------	---	--	---	---

**Phase 1 Trials are offered in Victoria at the following locations:**

Study Site	Contact	Email	Phone
Alfred Hospital (Prahran VIC 3004)	Clinical Trial Team	moncACT1@alfredhealthconnect.onmicrosoft.com	TBA
Austin Hospital (Heidelberg VIC 3084)	Samantha Chakar	samantha.chakar@austin.org.au	03 9496 3088
Barwon Health (Geelong VIC 3220)	Karen Aitken	cstu.manager@barwonhealth.org.au	03 4215 2758
Cabrini Malvern (Malvern VIC 3144)	Rochelle Woods	rwoods@cabrini.com.au	95083437
Epworth Hospital (Richmond VIC 3121)	Clinical Research Coordinator	ehjreissaticentre@epworth.org.au	0448 842 680 or 03 9426 8880
PASO Medical (Frankston VIC 3199)	Albert Goikman Clinical Trials Manager	ag@paso.com.au	03 91131307
Monash Health (Clayton VIC 3168)	Early Phase Research Study Coordinator	referrals.earlyphase@monashhealth.org	0474 769 510
Peter MacCallum Cancer Centre (Parkville VIC 3052)	Enquiries Line Coordinator	clinicaltrials.enquiries@petermac.org	03 8559 7456 (9am-2pm, Mon-Fri)
St Vincent's Hospital (Fitzroy VIC 3065)	Nadia Ranieri	oncology.research@svha.org.au	03 9231 3167
Western Health (St Albans VIC 3021)	Heike Raunow	CancerClinicalTrials@wh.org.au	03 83959136 or 0434915739

For patients not eligible for any of the above trials, and who have pancreatic cancer that has progressed, are intolerant or are ineligible for standard of care treatments, please consider a phase 1 trial. Clinicians can email or phone the contact listed with any enquiries. Patients, please contact your treating Medical Oncologist if you wish to discuss phase 1 trials.



PANCREATIC OR SOLID CANCER TRIALS OUTSIDE OF VICTORIA					
Trial Title	Targets (Genomic)	Target population <i>(Trial suitable for patients with this stage of pancreatic cancer)</i>	Treatment + Further Information <i>(What the study involves)</i>	Site <i>(Where the study is being offered)</i>	Contact Details <i>(Email the contact person listed with any enquiries)</i>
MountainTAP-30 (CA240-0030) A Randomized, Phase 2/3 Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion	MTAP deletion	PANCREATIC CANCER - METASTATIC/LOCALLY ADVANCED Inclusion: Untreated advanced pancreatic cancer Homozygous MTAP deletion	BMS-986504 Patients will receive gemcitabine and nab-paclitaxel combined with BMS-986504 (a novel PRMT5 inhibitor) or placebo. Further information: https://www.clinicaltrials.gov/study/NCT07076121	Royal Brisbane & Women's Hospital	amy.ives@health.qld.gov.au
				GenesisCare St Leonards North Shore Health Hub (NSW)	admin.northshore@genesiscare.com
				St John Of God Murdoch Hospital (WA)	Mel.Hernandez@sjog.org.au
AMG193 20230223 A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 in Combination with	MTAP deletion	PANCREATIC CANCER - METASTATIC/LOCALLY ADVANCED Inclusion: Pancreatic cancer	AMG 193 AMG 193 is a PMRT5 inhibitor which is administered orally. AMG 193 will be administered	GenesisCare St Leonards North Shore Health Hub (NSW)	admin.northshore@genesiscare.com



PANCREATIC OR SOLID CANCER TRIALS OUTSIDE OF VICTORIA					
Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
Other Therapies in Subjects with Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers with Homozygous MTAP-deletion AMG20230223		Homozygous MTAP-deletion Exclusion: Prior MAT2A inhibitor or PRMT5 inhibitor	with chemotherapy. Further information: https://www.cancer.nsw.gov.au/research-and-data/cancer-clinical-trials-in-nsw/find-a-cancer-clinical-trial-in-nsw/item?r=13988	Chris O'Brien Lifeshouse	jasmine.sell@lh.org.au * NO SLOTS CURRENTLY AVAILABLE*
<u>AMPLICITY (AMP945-202)</u> A Phase 1b/2a, Multicenter, Open Label Study of the Safety, Efficacy and Pharmacokinetics of Narmafotinib in Combination With Modified FOLFIRINOX in Pancreatic Cancer Patients	FAK	PANCREATIC CANCER - METASTATIC/LOCALLY ADVANCED (First line) Inclusion: Treatment naïve for metastatic disease	<u>Narmafotinib</u> Narmafotinib is an oral FAK inhibitor. Narmafotinib will be administered in combination with mFOLFIRINOX chemotherapy Further information: AMPLICITY Trial	GenesisCare St Leonards North Shore Health Hub (NSW)	admin.northshore@genesiscare.com
<u>KONQUER-101</u> A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.	RAS	ADVANCED OR METASTATIC SOLID CANCERS Inclusion: RAS mutant PDAC, CRC, NSCLC, or other solid tumour **NOTE: Opening late March 2026**	<u>BBO-11818</u> BBO-11818 is a pan-RAS inhibitor and will be administered alone or in combinations with chemotherapy and/or pembrolizumab Further information: https://clinicaltrials.gov/study/NCT06917079	GenesisCare St Leonards North Shore Health Hub (NSW)	admin.northshore@genesiscare.com



PANCREATIC OR SOLID CANCER TRIALS OUTSIDE OF VICTORIA					
Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
<p><u>CA233-0000/</u> <u>BMS-986484</u></p> <p>A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors</p>	CD40/FAP	<p>ADVANCED OR METASTATIC SOLID CANCERS</p> <p>Exclusion: History of ILD</p>	<p><u>BMS-986484</u></p> <p>BMS-986484 (a CD40/FAP bispecific agonist) is delivered as monotherapy or in combination with nivolumab</p> <p>Further information: https://www.cancer.nsw.gov.au/research-and-data/cancer-clinical-trials-in-nsw/find-a-cancer-clinical-trial-in-nsw/item?r=14232</p>	<p>St Vincent's Hospital Kinghorn Cancer Centre (NSW)</p> <p>Lyell McEwin Hospital (SA)</p>	<p>svhs.research@svha.org.au</p> <p>Health.NALHNCancerResearch@sa.gov.au</p>
<p><u>ALKOVE-1</u></p> <p>A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-to655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE-to1)</p>	ALK	<p>ADVANCED OR METASTATIC SOLID CANCERS</p> <p>Inclusion: ALK rearrangement or activating ALK mutation</p>	<p><u>NVL655</u></p> <p>NVL655 (neladalkib) is an oral selective ALK inhibitor.</p> <p>Further information: https://www.cancer.nsw.gov.au/research-and-data/cancer-clinical-trials-in-nsw/find-a-cancer-clinical-trial-in-nsw/item?r=13595</p>	Royal North Shore Hospital NSW	<p>PI: malinda.itchins@sydney.edu.au</p> <p>Trial coordinator: shirley.liang@health.nsw.gov.au</p>
<p><u>AT-0174-001</u></p> <p>A Phase I Study to Evaluate the Safety, Tolerability, Pharmacology, and Preliminary Efficacy of AT-0174 in Subjects with Advanced Solid Malignancies</p>	IDO1/TDO2	<p>ADVANCED OR METASTATIC SOLID CANCERS</p> <p>Inclusion: Progressed on available prior lines of therapy</p>	<p><u>AT-0174</u></p> <p>AT-0174 is a novel dual inhibitor of IDO1/TDO2</p> <p>Further information: https://www.anzctr.org.au/Trial</p>	Royal North Shore Hospital (NSW)	<p>PI: helen.wheeler@health.nsw.gov.au</p> <p>Trial Coordinator: wengqiong.yu@health.nsw.gov.au</p>



PANCREATIC OR SOLID CANCER TRIALS OUTSIDE OF VICTORIA					
Trial Title	Targets (Genomic)	Target population <i>(Trial suitable for patients with this stage of pancreatic cancer)</i>	Treatment + Further Information <i>(What the study involves)</i>	Site <i>(Where the study is being offered)</i>	Contact Details <i>(Email the contact person listed with any enquiries)</i>
<u>BGB-58067</u> A Phase 1a/b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-58067, an MTA-Cooperative PRMT5 Inhibitor in Patients With Advanced Solid Tumors	MTAP deficiency	ADVANCED OR METASTATIC SOLID CANCERS Inclusion: Any treatment line	BGB-58067 BGB-58067 is a PMRT5 inhibitor Further information: https://www.cancer.nsw.gov.au/research-and-data/cancer-clinical-trials-in-nsw/find-a-cancer-clinical-trial-in-nsw/item?r=14130	Blacktown Cancer & Haematology Centre (NSW)	William.dAvigdor@health.nsw.gov.au
				Westmead Hospital (NSW)	Adnan.Nagrial@health.nsw.gov.au
<u>GeneScreen 5FU</u> DPYD Genotype-guided dose Personalisation for Fluoropyrimidine prescribing in Cancer	DPYD	SOLID CANCERS – ALL STAGES Inclusion: Intention to treat with Fluoropyrimidine (FP) containing chemotherapy Exclusion: Prior FP containing chemotherapy prior to study entry.	DPYD genotyping Pre-emptive DPYD genotyping prior to commencing Fluoropyrimidine chemotherapy Further information: ANZCTR - Registration	Lake Macquarie Private Hospital (NSW)	ClinicalTrialsUnit.LMP@ramsayhealth.com.au
				Fiona Stanley Hospital (WA)	audrey.margery-Muir@health.wa.gov.au
<u>BAY3713372</u> A first in human study to evaluate the safety, tolerability, and pharmacokinetics, pharmacodynamics, and preliminary clinical activity of BAY 3713372, a novel 2 nd generation PRMT5 inhibitor in participants with MTAP deleted solid tumors	MTAP loss	ADVANCED OR METASTATIC SOLID CANCERS Inclusion Systemic Treatment naive or treatment exposed advanced pancreatic adenocarcinoma Homozygous MTAP deletion	BAY 3713372 BAY 3713372 is a novel 2 nd generation PRMT5 inhibitor. Further information: https://www.cancer.nsw.gov.au/research-and-data/cancer-clinical-trials-in-nsw/find-a-cancer-clinical-trial-in-nsw/item?r=14234	Chris O'Brien Lifehouse	teresa.nicholls@lh.org.au



PANCREATIC OR SOLID CANCER TRIALS OUTSIDE OF VICTORIA					
Trial Title	Targets (Genomic)	Target population <i>(Trial suitable for patients with this stage of pancreatic cancer)</i>	Treatment + Further Information <i>(What the study involves)</i>	Site <i>(Where the study is being offered)</i>	Contact Details <i>(Email the contact person listed with any enquiries)</i>
<p>AMG 410</p> <p>* LIMITED SLOTS AVAILABLE*</p> <p>A Phase 1/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors</p>	KRAS	<p>ADVANCED OR METASTATIC SOLID CANCERS</p> <p><i>(Exhausted standard of care)</i></p> <p>Inclusion: KRAS mutation or amplification Exhausted conventional treatment options Pancreatic cohort specified in part 2.</p>	<p>AMG 410</p> <p>AMG 410 is an oral pan-KRAS inhibitor and will be administered alone or in combination with pembrolizumab and panitumumab</p> <p>Further information: https://www.cancer.nsw.gov.au/research-and-data/cancer-clinical-trials-in-nsw/find-a-cancer-clinical-trial-in-nsw/item?r=14288</p>	Chris O'Brien Lifehouse	<p>jasmine.sell@lh.org.au</p> <p>* LIMITED SLOTS AVAILABLE*</p>
<p>OKN-4395-121</p> <p>A Phase 1, Open-label, Multicenter, Dose-escalation and Cohort Expansion Study of OKN4395, a Triple Antagonist of EP2, EP4, and DP1 Prostanoid Receptors, as Monotherapy and in Combination With Pembrolizumab, in Patients With Advanced Solid Tumors</p>	EP2, EP4, DP1	<p>ADVANCED OR METASTATIC SOLID CANCERS</p> <p>Inclusion: Phase 1a – Exhausted SOC Phase 1b – no more than 3 prior lines of therapy</p>	<p>OKN4395</p> <p>OKN4395 is a triple agonist of EP2, EP4, and DP1 prostanoid receptors. This will be administered alone or in combination with pembrolizumab</p> <p>Further information: https://www.cancer.nsw.gov.au/research-and-data/cancer-clinical-trials-in-nsw/find-a-cancer-clinical-trial-in-nsw/item?r=14182</p>	Chris O'Brien Lifehouse	teresa.nicholls@lh.org.au
<p>BNT326-01</p> <p>A Phase I/II, Open-label, Adaptive Two-part Trial to</p>	HER3	<p>ADVANCED OR METASTATIC SOLID CANCERS</p> <p>Inclusion:</p>	<p>BNT326</p> <p>BNT326 is a HER3 targeted</p>	One Clinical Research, Hollywood	<p>scott.mcgregor@oneclinicalresearch.com.au</p> <p>om.au</p>



PANCREATIC OR SOLID CANCER TRIALS OUTSIDE OF VICTORIA					
Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
Evaluate the Safety, Efficacy, Optimal Dose and Pharmacokinetics of BNT326 as Monotherapy and in Combination With Cancer Immunotherapies in Participants With Advanced Solid Tumors		Second or third line	ADC with a topoisomerase I inhibitor. Further information: https://cancertrialswa.zepi.com.au/clinical-trials/80123	Medical Centre, Nedlands WA	
KANDLELIT-014 A Phase 2, Open-Label, Multicenter, Tumor-agnostic Study of MK-1084 as Monotherapy and in Combination With Cetuximab, in Participants With KRAS G12C-Mutant, Advanced Solid Tumors (KANDLELIT-014)	KRAS G12C	ADVANCED OR METASTATIC SOLID CANCERS Inclusion: Progression on standard of care therapy	MK-1084 MK-1084 is an oral KRAS G12C inhibitor. Patients will be treated alone or in combination with cetuximab. Further information: https://clinicaltrials.gov/study/NCT07209111	Prince of Wales Hospital, NSW	SESLHD-POW-CTRUreferrals@health.nsw.gov.au
HD-PRiMe Feasibility of delivering High Dose Palliative Radiotherapy in patients with Metastatic malignancy	N/A	ADVANCED OR METASTATIC SOLID CANCERS Inclusion: Unsuitable for systemic treatment	Radiotherapy High dose palliative radiotherapy Further information: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=390482	Sunshine Coast University Hospital (QLD)	SC-Oncologytrials@health.qld.gov.au



PANCREATIC OR SOLID CANCER TRIALS OUTSIDE OF VICTORIA					
Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
<p><u>AK138D1</u></p> <p>A First-in-human, Phase I Study of Evaluating Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AK138D1 in the Treatment of Advanced Solid Tumors</p>	HER3	<p>ADVANCED OR METASTATIC SOLID CANCERS</p> <p>Inclusion: Exhausted conventional treatment</p>	<p><u>Patritumab Deruxtecan</u></p> <p>Patritumab Deruxtecan an anti-HER3 Antibody drug conjugate</p> <p>Further information: https://www.cancer.nsw.gov.au/research-and-data/cancer-clinical-trials-in-nsw/find-a-cancer-clinical-trial-in-nsw/item?r=14186</p>	Blacktown Cancer & Haematology Centre (NSW)	raymond.tangunan@health.nsw.gov.au
<p><u>BGB 53038</u></p> <p>A Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-53038, a Pan-KRAS Inhibitor, As Monotherapy or in Combinations in Patients with Advanced or Metastatic Solid Tumors with KRAS Mutations or Amplifications</p>	<p>KRAS mutation or amplification (excluding KRAS G12R)</p>	<p>ADVANCED OR METASTATIC SOLID CANCERS</p> <p>Inclusion: Evidence of KRAS mutation or wild-type amplification</p> <p>Exclusion: KRAS G12R mutation Prior treatment with other RAS targeting treatment</p>	<p><u>BGB-53038</u></p> <p>BGB-53038 is a pan-KRAS inhibitor.</p> <p>Further information: https://www.cancer.nsw.gov.au/research-and-data/cancer-clinical-trials-in-nsw/fin193d-a-cancer-clinical-trial-in-nsw/item?r=14188</p>	Blacktown Cancer & Haematology Centre (NSW)	raymond.tangunan@health.nsw.gov.au
				Westmead Hospital (NSW)	Adnan.Nagrial@health.nsw.gov.au



PANCREATIC CANCER TRIALS IN SINGAPORE					
Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
<p><u>LDOXIRI-PDAC-01</u></p> <p>A phase II study of metronomic capecitabine, oxaliplatin and UGT1A1 genotype-directed irinotecan in metastatic pancreatic cancer patients.</p>	NA	<p>METASTATIC/LOCALLY ADVANCED</p> <p>Inclusion: Systemic Treatment naive or treatment exposed advanced pancreatic adenocarcinoma</p>	<p>Metronomic capecitabine, oxaliplatin and UGT1A1 genotype directed irinotecan</p> <p>Further information: https://clinicaltrials.gov/study/NCT05929885?term=NCT05929885&rank=1b</p>	National Cancer Centre Singapore	honey.shwe.sin@nccs.com.sg
<p><u>Bayer 22931</u></p> <p>A first in human study to evaluate the safety, tolerability, and pharmacokinetics, pharmacodynamics, and preliminary clinical activity of BAY 3713372, a novel 2nd generation PRMT5 inhibitor in participants with MTAP deleted solid tumors</p>	MTAP loss	<p>ADVANCED OR METASTATIC SOLID CANCERS</p> <p>Inclusion Systemic Treatment naive or treatment exposed advanced pancreatic adenocarcinoma Homozygous MTAP deletion</p>	<p>BAY 3713372</p> <p>BAY 3713372 is a novel 2nd generation PRMT5 inhibitor.</p> <p>Further information: https://clinicaltrials.gov/study/NCT06914128</p>	National Cancer Centre Singapore	Wang.jue.lynn@nccs.com.sg
				National University Hospital Singapore	global-roche-genentech-trials@gene.com
<p><u>GO45416 (GDC-7035)</u></p> <p>A phase I/II Dose-Escalation and expansion study evaluating the safety, pharmacokinetics, and activity of GDC-7035 as a single agent and in combination with other anti-cancer therapies in patients with advanced solid tumors with a KRAS G12D mutation</p>	KRAS G12D	<p>METASTATIC/LOCALLY ADVANCED</p> <p>Inclusion: Systemic Treatment refractory KRAS G12D pancreatic adenocarcinoma</p>	<p>GDC-7035</p> <p>GDC-7035 is a KRAS G12D inhibitor</p> <p>Further information: https://clinicaltrials.gov/study/NCT06619587</p>	National Cancer Centre Singapore	Ye.xin@nccs.com.sg
				National University Hospital Singapore	global-roche-genentech-trials@gene.com



PANCREATIC CANCER TRIALS IN SINGAPORE					
Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
<p><u>PAUF-I</u></p> <p>A first in human phase I/2A, multicentre, open label study of evaluating the safety, tolerability, pharmacokinetics, and efficacy of PBP1510 in patients with advanced/metastatic pancreatic cancer</p>	<p>PAUF</p>	<p>METASTATIC/LOCALLY ADVANCED</p> <p>Inclusion: Systemic Treatment exposed pancreatic adenocarcinoma</p>	<p><u>PBP 1510</u></p> <p>PBP 1510 is an anti-PAUF antibody</p> <p>Further information: https://clinicaltrials.gov/study/NCT05141149</p>	<p>National Cancer Centre Singapore</p>	<p>Goh.mui.leng@singhealth.com.sg</p>
<p><u>EBC 129-01</u></p> <p>EBC 129-01 - A Phase 1A/B Study to Evaluate the Safety and Tolerability of EBC 129 as a Single Agent and in Combination with Pembrolizumab in Advanced Solid Tumours</p>	<p>anti N256-glycosylated CEACAM5 and CEACAM6</p>	<p>ADVANCED OR METASTATIC SOLID CANCERS</p> <p>Inclusion: Exhausted standard of care treatment options</p>	<p><u>EBC129</u></p> <p>EBC129 is an anti-N256-glycosylated CEACAM5 and CEACAM6 antibody drug conjugate. EBC129 will be administered alone or in combination with pembrolizumab</p> <p>Further information: https://clinicaltrials.gov/study/NCT05701527</p>	<p>National University Hospital Singapore</p>	<p>Venkateshan_Srirangam@eddc.sg</p>
<p><u>CA240-0030</u></p> <p>A Randomized, Phase 2/3 Study Comparing BMS-986504 in Combination with Nab-paclitaxel and Gemcitabine versus Placebo</p>	<p>MTAP deletion</p>	<p>METASTATIC/LOCALLY ADVANCED (First line)</p> <p>Inclusion: Untreated advanced pancreatic cancer</p>	<p><u>BMS-986504</u></p> <p>Patients will receive gemcitabine and nab-paclitaxel combined with BMS-986504 (a novel PRMT5</p>	<p>National University Hospital Singapore</p>	<p>Clinical.Trials@bms.com</p>



PANCREATIC CANCER TRIALS IN SINGAPORE					
Trial Title	Targets (Genomic)	Target population <i>(Trial suitable for patients with this stage of pancreatic cancer)</i>	Treatment + Further Information <i>(What the study involves)</i>	Site <i>(Where the study is being offered)</i>	Contact Details <i>(Email the contact person listed with any enquiries)</i>
in Participants with Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion		Homozygous MTAP deletion **Note: Activation March 27**	inhibitor) or placebo. Further information:		

PANCREATIC CANCER PREVENTION					
Trial Title	Targets (Genomic)	Target population <i>(Trial suitable for patients with this stage of pancreatic cancer)</i>	Treatment + Further Information <i>(What the study involves)</i>	Site <i>(Where the study is being offered)</i>	Contact Details <i>(Email the contact person listed with any enquiries)</i>
<u>APRISE</u> Assess the effectiveness of the Australian Pancreatic High-Risk Screening Program in identifying early-stage pancreatic cancer among high-risk individuals due to familial or genetic risk factors	NA	FAMILY HISTORY OF PANCREATIC CANCER Inclusion: High risk features for pancreatic cancer development	Screening Screening with endoscopic ultrasound or MRI for a period of 10 years Further information: https://trials.cancervic.org.au/details/vct1_actrn12624000421538	Epworth Health	EJReissatiCentre@epworth.org.au